Background: CB 1 cannabinoid receptors (CB 1 Rs) stimulate Gi/o-dependent signaling pathways. CB 1 R-mediated cAMP increases were proposed to result from Gs activation, but CB 1 R-stimulated GTPγ S binding to Gs has not heretofore been investigated. Methods: Three models of CB 1 R-stimulated cAMP production were tested: pertussis toxin disruption of Gi/o in N18TG2 cells; L341A/A342L-CB 1 R expressed in Chinese hamster ovary (CHO) cells; and CB 1 and D 2 dopamine receptors endogenously co-expressed in MN9D cells. cAMP was assayed by [
Introduction
The CB 1 cannabinoid receptor (CB 1 R) is highly expressed in the central nervous system and other tissues [1] , and is an important therapeutic target for neuropathic pain, multiple sclerosis, appetite modulation, curtailing nausea in cancer chemotherapy, cardiovascular and inflammatory diseases and neurodegenerative diseases (see reviews [2] [3] [4] [5] ). The CB 1 R is a G protein coupled receptor (GPCR) [6] [7] [8] [9] coupled to G proteins in signal transduction pathways that inhibit adenylyl cyclase activity, regulate ion channels, activate mitogen-activated protein kinase and focal adhesion kinase, and regulate expression of immediate early genes [10] . The CB 1 R selectively interacts with Gi/o proteins in the absence of exogenous agonists, such that a CB 1 R agonist can activate the effector by promoting dissociation of the G protein subunits, measured either by direct association in detergent solution or by determining the accumulation of the GTP analog [ 35 S]GTPγS bound to the Gα subunit [11] [12] [13] . A CB 1 R-Gs interaction has been suggested by results observed in three model systems. First, pertussis toxin treatment which precludes Gαi interaction with GPCRs increased cAMP accumulation, proposed to be due to Gαs interaction [14] [15] [16] . A second experimental system that investigated a CB 1 R activation of Gs was developed by the Kendall laboratory [17] , which noted that the CB 1 R contains a Leu341, Ala342 sequence in the third intracellular loop (IL3) which, when transposed, yielded the motif shown to mediate β-adrenergic receptor coupling to Gs. The Kendall laboratory developed a L341A/A342L-mutated CB 1 R to test the interaction with Gs in this model [17] . Third, when CB 1 Rs and D 2 dopamine receptors (D 2 Rs) are co-expressed, co-stimulation with agonists for the two Gi/o-coupled receptors led to an increase in cAMP production in striatal neurons [14] or human embryonic kidney (HEK293) cells expressing recombinant receptors [15, 16] . All of those studies investigated cAMP accumulation as an indicator of second messenger signaling that might occur if adenylyl cyclase were stimulated by Gs. However, those studies did not provide evidence to support a direct CB 1 RGs interaction by equilibrium association or by G protein activation.
In this study, we have determined cAMP changes and [
35 S]GTPγS binding using an antibody-targeted GTPγS scintillation proximity assay (SPA) approach [18, 19] to explore the CB 1 R-Gs interaction. This method determines activation of each G protein individually, thereby overcoming issues related to activation or inhibition of multiple G proteins and variability in sensitivity by different G proteins (see [20, 21] ). Using the previously reported models, we show that CB 1 R agonists promote [ 35 
S]GTPγS
binding to Gs to a much lesser extent than to Gi/o family, but that the increased cAMP accumulation fails to correlate with increased Gs activation. Rather, these manipulations reverse Gi/o family activation, leading us to conclude that an attenuated inhibitory influence of Gαi on adenylyl cyclase is responsible for the increased production of cAMP.
Materials and methods

Cell culture
N18TG2 neuroblastoma and MN9D hybrid neuron-neuroblastoma cells (a gift from Rong Chen, Univ. Michigan stock) were maintained as previously described [22] . Parental Chinese hamster ovary (CHO) cells stably transfected with either CB 1 R or L341A/A342L mutant CB 1 R (gifts from Debra Kendall, University of Connecticut) were grown at the same conditions as the neuronal cells, except that transfected cells were maintained under selection using 0.2 μg/mL G418 (Gemini Bio-Products, West Sacramento, CA, USA). Cells were as low passage as possible to obtain. Although we characterized the cells for mRNA and protein, we did not verify the sequence of the CB 1 R or G proteins from these cell lines. Quantitative reverse transcriptase polymerase chain reaction (qPCR) methods and data analyses have been previously described [22] . For immunocytochemistry, cells were plated at a density of 25,000 cells on 0.2 mg/mL poly-d-lysine-coated coverslips (Fisher Scientific, PA, USA). Media was removed and cells were rinsed twice in cold phosphate buffered saline (PBS). Cells were fixed with 4% formaldehyde for 15 min, and then permeabilized with 0.1% triton-X100 in PBS. Coverslips were incubated with primary antibodies [rabbit anti-CB 1 (Cayman Chemical, Ann Arbor, MI, USA) and mouse anti-D 2 (Santa Cruz, Santa Cruz, CA, USA)] at a dilution of 1:50 in 4% normal donkey serum in PBS at room temperature for 90 min, and then rinsed four times in PBS. Secondary antibodies (goat anti-rabbit and donkey anti-mouse) were added in 4% normal donkey serum in PBS at a dilution of 1:150 and incubated at room temperature for 50 min. Secondary antibodies (Alexa Fluor405 mouse anti-rabbit and Alexa Fluor488 donkey anti-mouse) were added in 4% normal donkey serum in PBS at a dilution of 1:150 and incubated at room temperature for 50 min. Coverslips were rinsed four times in PBS, mounted on slides with Prolong Gold, and stored for 24 h before acquiring images with an Olympus IX71 (40X/0.6Ph2, 0.55 NA) equipped with a Hamamatsu Digital CCD C8484-03G02 camera and digital image CellSens™ software (Olympus, Waltham, MA, USA).
cAMP assay
The indicated cells were grown to 90% confluence in 24-well plates, cell media was removed and cells were washed with (37 °C) physiologic saline solution-HEPES-bovine serum albumin (137 mM NaCl, 10 mM glucose, 5 mM KCl, 1 mM MgSO 4 , 1 mM CaCl 2 , 10 mM NaHEPES pH 7.4, and 0.5 mg/mL fatty acid-free bovine serum albumin) and incubated with phosphodiesterase inhibitors (100 μM 3-isobutyl-1-methylxanthine and 100 μM rolipram) plus cannabinoid or D 2 agonists or antagonists for 15 min at 37 °C. The adenylyl cyclase activator forskolin (Tocris Bioscience, Minneapolis, MN, USA) or secretin (Sigma, St. Louis, MO, USA) was added at the indicated concentrations for an additional 4 min. cAMP was determined as previously described [22] .
[
35 S]GTPγ S-binding and G protein antibody capture SPA N18TG2, MN9D or stably-transfected CHO cells were homogenized with a glass-glass homogenizer, and a post-nuclear (2000 × g supernatant) membrane fraction was prepared by sedimentation at 40,000 × g. The protein concentration was determined by the BCA kit (Pierce, Rockford, IL, USA) with bovine serum albumin as standard. [
35 S]GTPγS binding reactions were performed as previously described [22] . Cell membranes (5 μg) were incubated for 1 h at 30 °C with 500 pM [ 35 S]GTPγS ( PerkinElmer, Waltham, MA, USA), 10 μM GDP and CB 1 R or D 2 R ligands in 20 mM NaHEPES, pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , and 1 mM dithiothreitol. To determine binding to total G proteins, the reaction was terminated by filtration using a cell harvester and washing, followed by adding scintillation cocktail to the UniFilter plate. To determine specific binding to G proteins defined by antibody-targeted SPA, membranes were solubilized with 3% IGEPAL CA-630 (30 min, 0-4 °C) and incubated with primary antibodies [anti-Gαo, anti-Gαi1, anti-Gαi2, antiGαi3, anti-Gαi1/2/3 or anti-Gαs (Santa Cruz, Santa Cruz, CA, USA)] for 1 h. SPA beads coated with secondary IgG and the fluor (PerkinElmer, Waltham, MA, USA) were added for 30 min, the plates were centrifuged, and radioactivity was detected on a Top-Count microplate scintillation counter (PerkinElmer, Waltham, MA, USA). Non-specific binding (determined by adding 10 μM GTPγS to the assay mix) was subtracted from total binding to obtain specific binding. Basal binding was defined as specific binding in the absence of stimulating agonists, and agoniststimulated values were normalized to basal as 100%.
Statistical analysis
Graphs and statistical analyses were generated using Prism V software (GraphPad, La Jolla, CA, USA). For log dose-response experiments, EC 50 values were determined by non-linear regression analysis. All data are expressed as the mean±SEM, and were considered significantly different when p ≤ 0.05.
Results
CB 1 R synthetic and endocannabinoid agonists inhibit forskolin-and Gs-stimulated cAMP accumulation
The ability of cannabinoid agonists to inhibit cAMP accumulation in a Gi/o-sensitive manner in different cell models and in brain membranes became one of the most widely recognized signaling mechanisms for the CB 1 R (see reviews [23, 24] ). The CB 1 R response to agonists in the neuronal model N18TG2 neuroblastoma was determined in the preequilibrium, linear accumulation phase (4-min) (Figure 1 ). Incubation with 1 μM forskolin significantly increased cAMP accumulation in N18TG2 cells 10-fold over vehicle ( Figure 1A) . When the cells were incubated with 1 μM of endocannabinoid agonist 2-arachidonoylglycerol (2-AG), the fatty acid amide hydrolase-resistant methyl-anandamide (mAEA), the bicy-
(1-naphthyl)methanone (WIN55212-2), prior to forskolin, these agonists were able to significantly inhibit forskolinactivated cAMP accumulation.
Evidence suggesting coupling of CB 1 R to Gs in the brain was reported in the absence of forskolin: i.e. in globus pallidus slice preparations, WIN55212-2 inhibited cAMP production under conditions of forskolin-treatment, but increased cAMP production under basal conditions [25, 26] . In contrast, in the N18TG2 cells in the absence of forskolin, the CB 1 R agonists (1 μM) failed to produce a significant increase in cAMP accumulation compared with vehicle ( Figure 1B ). The small increases in cAMP accumulation were < 5% of forskolin-activated accumulation, and these increases were not reliably observed. The doseresponse curve for cannabinoid agonists indicated that forskolin-activated cAMP accumulation was inhibited by CP55940 (EC 50 = 3.11 nM) and WIN55212-2 (EC 50 = 7.4 nM) with no evidence for an increase in cAMP levels at any concentration of agonist ( Figure 1C ). These studies demonstrate that when forskolin is used to reversibly activate adenylyl cyclase, there is no evidence for a stimulatory response to these full agonists at any concentration. The studies also demonstrate that there is no apparent "inverse agonist" effect of SR141716 alone (1 μM) under forskolin activation ( Figure 1A ) or basal ( Figure 1B ) conditions. In order to demonstrate the effects of Gi on Gs-stimulated adenylyl cyclase, we stimulated the endogenous secretin receptor in the N18TG2 cells ( Figure 1D ). The CB 1 agonists inhibited secretin-stimulated adenylyl cyclase, as expected, for Gi acting to counteract the effects of Gs on adenylyl cyclase. In order to determine the effect that desensitization of the CB 1 R exerts on cannabinoid inhibition of cAMP accumulation, we treated N18TG2 cells with vehicle (control) or the full agonist CP55940 for 1 h, and then stimulated cAMP accumulation with secretin in the presence of vehicle or the CB 1 R agonists CP55940 or WIN55212-2. We observed a desensitization of the CB 1 R-mediated inhibition of cAMP accumulation in the secretin-stimulated cells ( Figure 1D ). This can be interpreted to mean that removing the inhibition by Gi allowed Gs to stimulate adenylyl cyclase without restraint. Desensitization of the WIN55212-2-mediated Gi response on basal adenylyl cyclase was also observed.
Preventing Gi/o coupling to CB 1 R does not augment CB 1 
R activation of Gs
Evidence that the CB 1 R is a GPCR linked to Gi/o came from studies using pertussis toxin treatment to ADP-ribosylate Gi/o family proteins and thereby prevents these G proteins from interacting with their GPCRs [27] . The suggestion of CB 1 R-Gs coupling is based on the notion that Gs binding will be augmented if Gi/o coupling is precluded by pertussis toxin, and is based solely on observations of increased cAMP production by CB 1 R agonists in pertussis toxin-treated neurons and CB 1 -CHO cells [14, 26, 28] . To investigate this mechanism, we used the SPA assay with N18TG2 cell membranes and found that CP55940 was able to stimulate [ , and SPA performed using the indicated anti-Gα antibody. Data are shown as the specific binding as a percent over basal, and are the mean±SEM of three or four independent experiments, and analyzed using unpaired, one-way Student's t-test; **significantly different from untreated controls, p < 0.001.
in Gs activation associated with pertussis toxin-mediated loss of Gi/o activation suggests that either the intrinsic efficacy of CB 1 R to activate Gs is small compared with Gi/o proteins, or that the population of CB 1 Rs capable of being coupled to Gi/o is not in a location that is able to be coupled to Gs. cAMP accumulation and G protein activation in the L341A/A342L-mutated CB 1 R Additional evidence linking CB 1 R and Gs came from studies in the Kendall laboratory using a CB 1 R mutant in which Leu341, Ala342 was replaced with Ala341, Leu342, resulting in the IL3 signature motif Ala-Leu-Lys-Thr (ALKT) identified in the Gs-coupled β 2 -adrenergic receptor [17] . Abadji and colleagues [17] characterized this mutant as having a nearly two-fold greater forskolin-activated cAMP accumulation compared with wild-type (WT) CB 1 R, and the CB 1 agonist-mediated inhibition was attenuated. Upon pertussis toxin treatment, which occludes Gi/o proteins from interacting with their receptors, the mutant CB 1 R exhibited a three-fold increase compared with WT in both forskolin-activated cAMP accumulation alone and the CP55940-mediated augmentation of forskolin-activated cAMP accumulation. This led the authors to suggest that "the mutant receptor couples to Gs more strongly than the WT receptor" and that the explanation for the attenuated inhibition of cAMP accumulation in the mutant receptor in the presence of agonist is that "the increased coupling to Gs partially obscured the inhibitory effect of agonists due to Gi coupling". We found that CB 1 ( Figure 3A) . In contrast, in L341A/A342L-mutated CB 1 -CHO cells in the absence of forskolin, cannabinoid agonists significantly stimulated cAMP accumulation over the vehicle control ( Figure 3B ). At maximally effective concentrations, CP55940, WIN55212-2 and 2-AG stimulated approximately 5-fold above basal, whereas mAEA stimulated only 2.5-fold. Cannabinoid agonists were not able to stimulate above basal cAMP levels in either parental CHO or CB 1 R-expressing CHO cells. These data are consistent with the explanation of Abadji and colleagues that the L341A/A342L-mutated CB 1 R couples to Gs in CHO cells, and in addition, indicate that mAEA is a partial agonist compared with the other ligands in this response.
To test this hypothesis, we investigated the effect of this mutation on G protein coupling using the SPA [ in the 10 nM to 1 μM range ( Figure 3D ). These data suggest that CP55940 behaves as an inverse agonist for the L341A/ A342L-mutated CB 1 R coupling to Gi1/2/3.
Effect of CB 1 R-D 2 R interaction on cAMP accumulation
CB 1 R-D 2 R co-activation led to an increased cAMP production that could be interpreted as an enhancement of CB 1 RGs interaction [14] [15] [16] . We examined CB 1 R-D 2 R interaction using a mesencephalic-derived neuron-N18TG2 hybrid cell line, MN9D, which has gained popularity as a model of central nervous system (CNS) dopaminergic neurons in studies related to neurotoxicity, oxidative stress, and neurodegenerative diseases [29] [30] [31] [32] [33] . The endogenous expression of CB 1 R and D 2 R is comparable in MN9D cells as determined by qPCR analysis ( Figure 4A ) and immunocytochemical studies ( Figure 4B ). cAMP production could depend upon which isoform of adenylyl cyclase is expressed in the MN9D cells, as each isoform family responds to Gi/o regulation in a different pattern [34, 35] . Using qPCR, we found that MN9D cells express AC6 at levels 3-fold greater than AC3 and 10-fold greater than AC1 or AC4, and a similar pattern exists for N18TG2 cells (Figure 4C and D). In MN9D cells, CB 1 agonist HU210 inhibited forskolinactivated cAMP accumulation in a concentration-dependent fashion ( Figure 5A ). Quinpirole (100 nM) alone inhibited cAMP accumulation and augmented the inhibition at all concentrations of HU210 ( Figure 5A ). N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) (1 μM) reversed the inhibition mediated by 100 nM HU210 or CP55940 (data not shown), demonstrating the requirement for CB 1 R for this response. Forskolin activated adenylyl cyclase in a concentration-dependent fashion. Importantly, as the forskolin concentration diminished (approaching basal), the inhibition by combined CB 1 R-D 2 R agonists was converted to a stimulation ( Figure 5B ). This phenomenon is readily observed when the data are redrawn as a percent of the activation at each forskolin concentration ( Figure 5C ). The quinpirole-HU210 combination increased cAMP accumulation in the presence of low concentrations of forskolin (50 nM) ( Figure 5D ), vehicle (basal) ( Figure 5E ) or secretin (30 nM) ( Figure 5F ). To understand the role of D 2 Rs in stimulated cAMP accumulation, cells were incubated with HU210 (1 μM) plus D 2 agonists quinpirole or sumanirole (100 nM). Both agonists inhibited maximal forskolin (1 μM)-activated cAMP production, but stimulated sub-maximal forskolin (50 nM) or basal responses ( Figure 6A and B) . D 2 antagonist raclopride reversed the stimulation of cAMP accumulation by combined CB 1 R-D 2 R agonists to below 100% levels, resulting in the HU210-inhibited response.
We explored the G protein activation in CB 1 R-D 2 R co-stimulated membranes from MN9D cells. HU210 
Discussion
Experimental models of CB 1 R-stimulated cAMP production: Gi/o activation is attenuated
The goal of these studies was to address the question of whether the CB 1 R could couple to Gs. We found that Gs could be activated by CB 1 R stimulation, but with poor efficacy compared with Gi/o proteins ( Figure 2B ). We postulated that in a state of fewer Gi/o proteins, the CB 1 R might favor an interaction with Gs. However, this did not appear to be the case: treatment of cells with pertussis toxin, a well-known tool to abolish the ability of Gi/o proteins to interact with GPCRs, failed to significantly affect CB 1 R-mediated Gs activation ( Figure 2B ). Furthermore, cannabinoid agonists failed to activate Gi via a CB 1 R mutated to a dysfunctional G protein regulatory motif, whereas there was no effect on Gs activation (Figure 3) . Finally, co-stimulation of endogenously expressed CB 1 R and D 2 R resulted in increased cAMP production ( Figures 5 and 6 ) concurrently with reduced Gi/o activation (Figure 7) . Thus, instead of biasing the signaling to an alternative G protein, these manipulations reduced the availability of functional Gαi/o during CB 1 R signal transduction.
Following the identification of dysfunctional signal transduction resulting from the L341A/A342L mutation [17] , investigations of the structure of the CB 1 R IL3 by the Kendall and Mierke laboratories indicated that the mutation resides within the juxtamembrane C-terminus region of the IL3 at the first helical turn of Helix 6 [36] . Peptides that mimicked the IL3 domain could compete for the association of Gαi1 and Gαi2 with the CB 1 R [12, 37] . An IL3 C-terminus peptide, but not the L341A,A342L-mutated homologous peptide, could stimulate the GTPase activity of purified Gαi1 [38] . This was attributed to the requirement for a helical structure of the IL3 C-terminus peptide to interface with Gαi1, which is not formed by the mutant peptide [38] . These studies provide evidence to support a function for this CB 1 R domain in optimal Gi protein activation.
Consistent with the proposal of reduced functional Gi/o, Jarrahian and colleagues [16] examined a model of HEK293 cells in which the D 2 R was stably expressed and the CB 1 R was transiently transfected into the cell line. In their HEK293-D 2 R-CB 1 R cells, CP55940 increased forskolinstimulated cAMP accumulation to nearly 150% compared with forskolin alone. Because this stimulation could be reversed by over-expression of Gαi1, it was postulated that the presence of D 2 Rs reduced Gi protein availability to interact with the CB 1 R [16] . The mechanism for the CB 1 R-D 2 R regulation of G protein activation is not entirely clear. However, evidence for heterodimerization has been provided by Kearn and colleagues, who demonstrated coimmunoprecipitation when the HEK293 cells exogenously expressing both receptors were treated with agonists for each receptor [15] .
It should be noted that the data presented herein do not address constitutive activity of CB 1 or D 2 receptors in the absence of exogenous ligands. To define the "basal" stimulation of GTPγS binding or cAMP accumulation as "constitutive", we rely on the reduction of the response by an inverse agonist (e.g. SR141716) [39] [40] [41] . In any biological system, the abundance of endogenously produced endocannabinoids is an important determinant of whether the CB 1 R is under the influence of high "endocannabinoid tone" that could be reversed by a competitive antagonist (for discussion, see [42] ). CHO cells express phospholipase C and diacylglycerol lipase [43, 44] , as do neuronal cell lines (Howlett, unpublished observations) , enzymes that govern production of the endocannabinoid 2-AG. This suggests the necessity of testing responses to a diaceylglycerol lipase inhibitor to demonstrate whether forskolin-activated cAMP accumulation can be influenced by endocannabinoids produced by the cultured cells.
The activation state of the adenylyl cyclase determines the outcome of inhibition or stimulation
Using the N18TG2 model, our laboratory has not been able to observe a stimulation of cAMP accumulation by any class of CB 1 R agonists when the adenylyl cyclase is activated by forskolin ( Figure 1A ) or under conditions of stimulation by a Gs-coupled receptor ( Figure 1D ). Increases in basal adenylyl cyclase activity by CB 1 R agonists are small when observed, and are not reproducible between experiments. For this reason, we chose to investigate models in which CB 1 R-mediated stimulation of cAMP production had been reliably demonstrated.
We noted that stimulation of CB 1 R in L341A,A342L-CB 1 -CHO cells in the basal state resulted in an augmentation of cAMP accumulation in cells. In our studies, cannabinoid agonists elicited an inhibition of forskolin-activated adenylyl cyclase in the mutated as well as the WT CB 1 R. These data diverge from the original report in which the L341A/ A342L-CB 1 -CHO cells incurred a significant attenuation of cannabinoid inhibition of forskolin-activated cAMP production (from about 50% in WT to 20% in mutated) [17] . The Abadji report demonstrated that following treatment with pertussis toxin, the forskolin-activated cAMP accumulation could be increased approximately two-fold in WT and five-fold in mutated L341A,A342L-CB 1 -CHO cells, indicating that the forskolin had not attained a full activation of adenylyl cyclase in those studies [17] . This suggests that the Kendall assays more closely resembled the partially activated adenylyl cyclase state that our studies show in Figure 5C .
The adenylyl cyclase could be activated by Gs rather than forskolin to observe inhibition by cannabinoid agonists. The Abadji report demonstrated that after cholera toxin pre-treatment to convert Gαs to a constitutively active state, CP55940 promoted an inhibition of cAMP accumulation in cells expressing either WT or mutated CB 1 R [17] . Thus, irrespective of the source of the activated Gs, the CB 1 R-mediated Gαi release attenuated the highly Gs-stimulated adenylyl cyclase activity. Glass and Felder showed that in CB 1 -CHO cells that had been treated with cholera toxin, HU210 at low concentrations (0.01 to 1 nM) produced an inhibition of cAMP production, whereas this curve was reversed to a limited extent at higher HU210 concentrations (10 nM to 1 μM) [14] . It would be difficult to envision that this could be attributed to Gs activation above that which had already been activated by cholera toxin. It could be that at these high concentrations of cannabinoid agonist, other influences can affect the receptor-G protein-adenylyl cyclase complex.
The same requirement for an activated adenylyl cyclase was observed when we studied MN9D cells, a model of interacting CB 1 R and D 2 R. At higher levels of activation by forskolin, dual stimulation of CB 1 R and D 2 R using HU210 plus quinpirole resulted in an inhibition of cAMP accumulation. In contrast, simultaneous stimulation of both receptors in the presence of low concentrations, or in the absence of forskolin, resulted in an augmentation of cAMP accumulation in MN9D cells. These results are consistent with the Glass and Felder data [14] , showing the stimulatory effect with a low concentration (50 nM) of forskolin. However, our findings differ from those of Jarrahian and colleagues, who reported increased cAMP accumulation by 1 or 10 μM CP55940 in HEK293-D 2 R-CB 1 R cells in the presence of of forskolin (10 μM) even in the absence of a D 2 agonist [16] . It is not clear how much these two receptors had been over-expresssed, compared to the MN9D cells which express these receptors endogenously. If receptors in HEK293-D 2 R-CB 1 R cells were expressed in great enough abundance to activate Gi or Gs proteins in the absence of agonist stimulation, the stoichiometry of signaling proteins would be very different between this model and the MN9D cells.
Distinctly different responses to cannabinoid agonists were demonstrated in a systematic analysis of recombinant adenylyl cyclase isoforms and CB 1 R co-expressed in COS-7 cells [45] . HU210 or WIN55212-2 inhibited cAMP accumulation by > 50% in cells that co-expressed either AC5 or AC6 isoforms stimulated by either 1 μM forskolin or thyrotropin (via an exogenously expressed Gs-coupled thyrotropin receptor). A similar 50% inhibition was observed for the Ca 2+ -calmodulin-stimulated AC1 or AC8 isoforms [45] . This is in contrast to the augmentation of cAMP production observed in cells that co-expressed any of the AC2/AC4/AC7 family members. For those adenylyl cyclase isoforms, the stimulation by HU210 or WIN55212-2 was only about 10%-20% above that stimulated by the Gscoupled TSH receptor or a constitutively active Gαs [45] . This augmentation could be attributed to an amplification of the Gαs response by the Gβγ released from Gi [34] . As Gαi levels are reduced, the enzymatic activity increases, leading to increased concentration of cAMP. The images of the catalytic domain of adenylyl cyclase with Gαs and Gαi are taken from Sunahara and Taussig [34] .
Proposal of a model
The Gαi/o released by CB 1 R stimulation acts at the Gαi binding site to suppress the activation of adenylyl cyclase (see Figure 8) . Basal, as well as Gαs-stimulated and forskolin-activated adenylyl cyclase, can be attenuated in the presence of Gαi. When Gi/o signaling is reduced by Gαi/o dysfunction (pertussis toxin) or CB 1 R dysfunction (IL3 mutation or D 2 R influence), this Gαi/o-mediated suppression of basal as well as low activity Gs-stimulated adenylyl cyclase is now relieved. The greater the activation by forskolin (which facilitates the juxtaposition of the intracellular catalytic domains of the adenylyl cyclase enzyme, thereby activating the enzyme) or Gαs, the less relief of the Gαi suppression will be evident. The GPCR(s) responsible for releasing Gαs are cell-type specific and would depend on the local scaffolding of GPCRs, G proteins and adenylyl cyclases. Alternative mechanisms by which the CB 1 R could stimulate adenylyl could include: direct coupling to and activation of Gs, or coupling to and activation of Gi/o to release Gβγ, thereby augmenting AC2/AC4/AC7. In the MN9D (shown here) and N18TG2 (data not shown) cells, (1) CB 1 R is coupled predominantly to activate Gi/o proteins and the conditions that increase cAMP also attenuate Gi/o activation; (2) the activation of Gs is not augmented under conditions that increase cAMP production; and (3) AC6 predominates over other isoforms of adenylyl cyclase, thereby providing the mechanism by which reduced availability of Gαi could allow Gαs-stimulated enzyme activity.
Implications for biased signaling
Much attention has been given to biased signaling by the 7-TM receptors, particularly with respect to the development of agonists that can select for either a G protein response or a beta-arrestin response [46, 47] . However, the emphasis on distinguishing between G protein and beta-arrestin may have turned our attention away from the implications of biased signaling within the G proteins associated with the GPCR. It appears that the currently available agonists for CB 1 R promote a preference for coupling to Gi/o family proteins (Eldeeb and Howlett, unpublished observations). However, within the Gi/o family, it appears that these agonists can distinguish which Gi/o subtypes are effectively activated and dissociated from the CB 1 R [48, 49] . Using the present technology, it is now possible to search among the current orthosteric agonists to determine if any of these have the potential to promote coupling and/or activation of G proteins other than the Gi/o family. We recently reported that over-expression of the small CB 1 R-associated cannabinoid receptor interacting protein 1a (CRIP1a) was able to diminish the activation of Gi3, but promote the activation of Gi1 and Gi2 in the N18TG2 model system [22] . Thus, it is possible that interacting proteins and small molecule allosteric modulators can bias the CB 1 R signaling for Gi/o family or non-Gi/o proteins. Perhaps orthosteric ligands or allosteric modulators that select for unique G protein or beta-arrestin subtypes can be developed for pharmacotherapeutic interventions of the future.
